CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia

The heterogeneous response of acute myeloid leukemia (AML) to current anti‐leukemic therapies is only partially explained by mutational heterogeneity. We previously identified GPR56 as a surface marker associated with poor outcome across genetic groups, which characterizes two leukemia stem cell (LS...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Lixiazi, Arnold, Christian, Thoma, Judith, Rohde, Christian, Kholmatov, Maksim, Garg, Swati, Hsiao, Cheng‐Chih, Viol, Linda, Zhang, Kaiqing, Sun, Rui, Schmidt, Christina, Janssen, Maike, MacRae, Tara, Huber, Karin, Thiede, Christian, Hébert, Josée, Sauvageau, Guy, Spratte, Julia, Fluhr, Herbert, Aust, Gabriela, Müller‐Tidow, Carsten, Niehrs, Christof, Pereira, Gislene, Hamann, Jörg, Tanaka, Motomu, Zaugg, Judith B, Pabst, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988201/
https://www.ncbi.nlm.nih.gov/pubmed/35253392
http://dx.doi.org/10.15252/emmm.202114990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988201/
https://www.ncbi.nlm.nih.gov/pubmed/35253392
http://dx.doi.org/10.15252/emmm.202114990

Ejemplares similares